Over 100 cases have now been performed with OMNIlife science’s OMNIBotics® Active Spacer in its multi-center U.S. clinical study.
The study is assessing the combination of robotic-assisted bone cutting with active soft tissue management at five sites; more are slated to enter the study over several months. Results from the first four sites mirror the positive outcomes observed in the Australian pilot program underway since 1Q17.
Active Spacer is reportedly the only available system that supports predictive balance of ligaments through dynamic, real-time feedback across the entire range of motion, that can deliver computer calculated, robotic-assisted bone cutting.
Over 100 cases have now been performed with OMNIlife science's OMNIBotics® Active Spacer in its multi-center U.S. clinical study.
The study is assessing the combination of robotic-assisted bone cutting with active soft tissue management at five sites; more are slated to enter the study over several months. Results from the first four sites...
Over 100 cases have now been performed with OMNIlife science’s OMNIBotics® Active Spacer in its multi-center U.S. clinical study.
The study is assessing the combination of robotic-assisted bone cutting with active soft tissue management at five sites; more are slated to enter the study over several months. Results from the first four sites mirror the positive outcomes observed in the Australian pilot program underway since 1Q17.
Active Spacer is reportedly the only available system that supports predictive balance of ligaments through dynamic, real-time feedback across the entire range of motion, that can deliver computer calculated, robotic-assisted bone cutting.
Copy to clipboard 
